199 related articles for article (PubMed ID: 37127754)
1. Acetyl-CoA biosynthesis drives resistance to histone acetyltransferase inhibition.
Bishop TR; Subramanian C; Bilotta EM; Garnar-Wortzel L; Ramos AR; Zhang Y; Asiaban JN; Ott CJ; Rock CO; Erb MA
Nat Chem Biol; 2023 Oct; 19(10):1215-1222. PubMed ID: 37127754
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
Lasko LM; Jakob CG; Edalji RP; Qiu W; Montgomery D; Digiammarino EL; Hansen TM; Risi RM; Frey R; Manaves V; Shaw B; Algire M; Hessler P; Lam LT; Uziel T; Faivre E; Ferguson D; Buchanan FG; Martin RL; Torrent M; Chiang GG; Karukurichi K; Langston JW; Weinert BT; Choudhary C; de Vries P; Van Drie JH; McElligott D; Kesicki E; Marmorstein R; Sun C; Cole PA; Rosenberg SH; Michaelides MR; Lai A; Bromberg KD
Nature; 2017 Oct; 550(7674):128-132. PubMed ID: 28953875
[TBL] [Abstract][Full Text] [Related]
3. 6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site.
Ghizzoni M; Wu J; Gao T; Haisma HJ; Dekker FJ; George Zheng Y
Eur J Med Chem; 2012 Jan; 47(1):337-44. PubMed ID: 22100137
[TBL] [Abstract][Full Text] [Related]
4. Modulating acetyl-CoA binding in the GCN5 family of histone acetyltransferases.
Langer MR; Fry CJ; Peterson CL; Denu JM
J Biol Chem; 2002 Jul; 277(30):27337-44. PubMed ID: 11994311
[TBL] [Abstract][Full Text] [Related]
5. Valproic acid exposure decreases Cbp/p300 protein expression and histone acetyltransferase activity in P19 cells.
Lamparter CL; Winn LM
Toxicol Appl Pharmacol; 2016 Sep; 306():69-78. PubMed ID: 27381264
[TBL] [Abstract][Full Text] [Related]
6. Analysis of p300/CBP histone acetyltransferase regulation using circular permutation and semisynthesis.
Karukurichi KR; Wang L; Uzasci L; Manlandro CM; Wang Q; Cole PA
J Am Chem Soc; 2010 Feb; 132(4):1222-3. PubMed ID: 20063892
[TBL] [Abstract][Full Text] [Related]
7. Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: implications for histone acetyltransferase evolution and function.
Wang L; Tang Y; Cole PA; Marmorstein R
Curr Opin Struct Biol; 2008 Dec; 18(6):741-7. PubMed ID: 18845255
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of anticancer activity of CBP/p300 inhibitors - Features of their classes, intracellular targets and future perspectives of their application in cancer treatment.
Strachowska M; Robaszkiewicz A
Pharmacol Ther; 2024 May; 257():108636. PubMed ID: 38521246
[TBL] [Abstract][Full Text] [Related]
9. Structure of the p300 histone acetyltransferase bound to acetyl-coenzyme A and its analogues.
Maksimoska J; Segura-Peña D; Cole PA; Marmorstein R
Biochemistry; 2014 Jun; 53(21):3415-22. PubMed ID: 24819397
[TBL] [Abstract][Full Text] [Related]
10. E2A proteins enhance the histone acetyltransferase activity of the transcriptional co-activators CBP and p300.
Hyndman BD; Thompson P; Bayly R; Côté GP; LeBrun DP
Biochim Biophys Acta; 2012 May; 1819(5):446-53. PubMed ID: 22387215
[TBL] [Abstract][Full Text] [Related]
11. Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor.
Poux AN; Cebrat M; Kim CM; Cole PA; Marmorstein R
Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14065-70. PubMed ID: 12391296
[TBL] [Abstract][Full Text] [Related]
12. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator.
Liu X; Wang L; Zhao K; Thompson PR; Hwang Y; Marmorstein R; Cole PA
Nature; 2008 Feb; 451(7180):846-50. PubMed ID: 18273021
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship and antitumor activity of 1,4-pyrazine-containing inhibitors of histone acetyltransferases P300/CBP.
Nie S; Wu F; Wu J; Li X; Zhou C; Yao Y; Song Y
Eur J Med Chem; 2022 Jul; 237():114407. PubMed ID: 35512565
[TBL] [Abstract][Full Text] [Related]
14. Application of a fluorescent histone acetyltransferase assay to probe the substrate specificity of the human p300/CBP-associated factor.
Trievel RC; Li FY; Marmorstein R
Anal Biochem; 2000 Dec; 287(2):319-28. PubMed ID: 11112280
[TBL] [Abstract][Full Text] [Related]
15. Discovery of berberine analogs as potent and highly selective p300/CBP HAT inhibitors.
Zhong X; Deng H; Long M; Yin H; Zhong Q; Zheng S; Gong T; He L; Wang G; Sun Q
Bioorg Chem; 2023 Sep; 138():106597. PubMed ID: 37245245
[TBL] [Abstract][Full Text] [Related]
16. Catalytic mechanism and function of invariant glutamic acid 173 from the histone acetyltransferase GCN5 transcriptional coactivator.
Tanner KG; Trievel RC; Kuo MH; Howard RM; Berger SL; Allis CD; Marmorstein R; Denu JM
J Biol Chem; 1999 Jun; 274(26):18157-60. PubMed ID: 10373413
[TBL] [Abstract][Full Text] [Related]
17. Bisubstrate analogue structure-activity relationships for p300 histone acetyltransferase inhibitors.
Sagar V; Zheng W; Thompson PR; Cole PA
Bioorg Med Chem; 2004 Jun; 12(12):3383-90. PubMed ID: 15158807
[TBL] [Abstract][Full Text] [Related]
18. Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor.
Bowers EM; Yan G; Mukherjee C; Orry A; Wang L; Holbert MA; Crump NT; Hazzalin CA; Liszczak G; Yuan H; Larocca C; Saldanha SA; Abagyan R; Sun Y; Meyers DJ; Marmorstein R; Mahadevan LC; Alani RM; Cole PA
Chem Biol; 2010 May; 17(5):471-82. PubMed ID: 20534345
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of the p300 HAT activity by HIV-1 Tat on chromatin DNA.
Deng L; Wang D; de la Fuente C; Wang L; Li H; Lee CG; Donnelly R; Wade JD; Lambert P; Kashanchi F
Virology; 2001 Oct; 289(2):312-26. PubMed ID: 11689053
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of p300 specific histone acetyltransferase inhibition by small molecules.
Arif M; Pradhan SK; Thanuja GR; Vedamurthy BM; Agrawal S; Dasgupta D; Kundu TK
J Med Chem; 2009 Jan; 52(2):267-77. PubMed ID: 19086895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
